Immune Dysfunction and Infections in Patients With Cirrhosis

Clinical Gastroenterology and Hepatology

Volumn 9, Issue 9, 2011, Pages 727-738

  Bonnel, Alexander R ^a   Bunchorntavakul, Chalermrat ^a   Reddy, K Rajender ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Ascites; Inflammation; Liver Disease; Therapy

Indexed keywords

ALBUMIN; BETA LACTAM; CEFOTAXIME; CEFTAZIDIME; CEFTIZOXIME; CEFTRIAXONE; CIPROFLOXACIN; HLA DR ANTIGEN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 4; INTERLEUKIN 6; LEVOFLOXACIN; MACROLIDE; NITRIC OXIDE; NORFLOXACIN; OFLOXACIN; PHOSPHOLIPASE C; PROSTAGLANDIN E2; SULFAMETHOXAZOLE; TRIMETHOPRIM; TUFTSIN; TUMOR NECROSIS FACTOR ALPHA;

AEROMONAS; ALCOHOL CONSUMPTION; ANTIBIOTIC THERAPY; ANTIGEN EXPRESSION; ASCITES; BACTERIAL CLEARANCE; BACTERIAL ENDOCARDITIS; BACTERIAL PERITONITIS; BACTERIAL TRANSLOCATION; BACTERICIDAL ACTIVITY; CANDIDA; CELL SPREADING; CELL VOLUME; CHEMOTAXIS; CIRRHOSIS ASSOCIATED IMMUNE DYSFUNCTION SYNDROME; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; COMMUNITY ACQUIRED PNEUMONIA; COMPUTER ASSISTED TOMOGRAPHY; CRYPTOCOCCUS NEOFORMANS; CYTOKINE STORM; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG DOSE COMPARISON; EDEMA; ENDOTHELIUM CELL; ENTEROBACTERIACEAE; ENTEROCOCCUS; ENZYME ACTIVITY; ESCHERICHIA COLI; GASTROINTESTINAL HEMORRHAGE; HOSPITAL INFECTION; HUMAN; HYPERAMMONEMIA; HYPONATREMIA; IMMUNOPATHOLOGY; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INFECTION RISK; KIDNEY FAILURE; KLEBSIELLA; LISTERIA MONOCYTOGENES; LIVER CIRRHOSIS; MALNUTRITION; MORTALITY; MYCOBACTERIUM TUBERCULOSIS; MYCOSIS; NEUTROPHIL; NEUTROPHIL COUNT; NUCLEAR MAGNETIC RESONANCE IMAGING; PERITONITIS; PHAGOCYTOSIS; PLESIOMONAS SHIGELLOIDES; PRIMARY SCLEROSING CHOLANGITIS; PROGNOSIS; PSEUDOMONAS AERUGINOSA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETICULOENDOTHELIAL CELL; RETICULOENDOTHELIAL SYSTEM; REVIEW; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SEPTIC SHOCK; SOFT TISSUE INFECTION; SPONTANEOUS BACTERIAL PERITONITIS; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS AGALACTIAE; STREPTOCOCCUS PNEUMONIAE; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TREATMENT FAILURE; TUBERCULOSIS; URINARY TRACT INFECTION; VACCINATION; VIBRIO CHOLERAE; VIBRIO PARAHAEMOLYTICUS; VIBRIO VULNIFICUS; YERSINIA; YERSINIA ENTEROCOLITICA; YERSINIA PSEUDOTUBERCULOSIS;

COMMUNICABLE DISEASES; CROSS INFECTION; HUMANS; IMMUNE SYSTEM DISEASES; IMMUNOCOMPROMISED HOST; LIVER CIRRHOSIS;

EID: 80052030974     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2011.02.031     Document Type: Review

References (146)

1. Tandon P., Garcia-Tsao G. Bacterial infections, sepsis, and multiorgan failure in cirrhosis. Semin Liver Dis 2008, 28:26-42.
2. Arvaniti V., D'Amico G., Fede G., et al. Infections in patients with cirrhosis increase mortality 4-fold and should be used in determining prognosis. Gastroenterology 2010, 1256:1246-1256. e1241-e1245.
3. Fernández J., Navasa M., Gómez J., et al. Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis. Hepatology 2002, 35:140-148.
4. Borzio M., Salerno F., Piantoni L., et al. Bacterial infection in patients with advanced cirrhosis: a multicentre prospective study. Dig Liver Dis 2001, 33:41-48.
5. Runyon B.A., Squier S., Borzio M. Translocation of gut bacteria in rats with cirrhosis to mesenteric lymph nodes partially explains the pathogenesis of spontaneous bacterial peritonitis. J Hepatol 1994, 21:792-796.
6. Garcia-Tsao G., Wiest R. Gut microflora in the pathogenesis of the complications of cirrhosis. Best Pract Res Clin Gastroenterol 2004, 18:353-372.
7. Ghassemi S., Garcia-Tsao G. Prevention and treatment of infections in patients with cirrhosis. Best Pract Res Clin Gastroenterol 2007, 21:77-93.
8. Katz S., Jimenez M.A., Lehmkuhler W.E., et al. Liver bacterial clearance following hepatic artery ligation and portocaval shunt. J Surg Res 1991, 51:267-270.
9. Wasmuth H.E., Kunz D., Yagmur E., et al. Patients with acute on chronic liver failure display "sepsis-like" immune paralysis. J Hepatol 2005, 42:195-201.
10. Fiuza C., Salcedo M., Clemente G., et al. In vivo neutrophil dysfunction in cirrhotic patients with advanced liver disease. J Infect Dis 2000, 182:526-533.
11. Christou L., Pappas G., Falagas M.E. Bacterial infection-related morbidity and mortality in cirrhosis. Am J Gastroenterol 2007, 102:1510-1517.
12. Trevisani F., Castelli E., Foschi F.G., et al. Impaired tuftsin activity in cirrhosis: relationship with splenic function and clinical outcome. Gut 2002, 50:707-712.
13. Garfia C., García-Ruiz I., Solís-Herruzo J.A. Deficient phospholipase C activity in blood polimorphonuclear neutrophils from patients with liver cirrhosis. J Hepatol 2004, 40:749-756.
14. Laffi G., Carloni V., Baldi E., et al. Impaired superoxide anion, platelet-activating factor, and leukotriene B4 synthesis by neutrophils in cirrhosis. Gastroenterology 1993, 105:170-177.
15. Shawcross D.L., Wright G.A., Stadlbauer V., et al. Ammonia impairs neutrophil phagocytic function in liver disease. Hepatology 2008, 48:1202-1212.
16. Kusaba N., Kumashiro R., Ogata H., et al. In vitro study of neutrophil apoptosis in liver cirrhosis. Intern Med 1998, 37:11-17.
17. Liles W.C., Kiener P.A., Ledbetter J.A., et al. Differential expression of Fas (CD95) and Fas ligand on normal human phagocytes: implications for the regulation of apoptosis in neutrophils. J Exp Med 1996, 184:429-440.
18. Ono Y., Watanabe T., Matsumoto K., et al. Opsonophagocytic dysfunction in patients with liver cirrhosis and low responses to tumor necrosis factor-alpha and lipopolysaccharide in patients' blood. J Infect Chemother 2004, 10:200-207.
19. Runyon B.A., Morrissey R.L., Hoefs J.C., et al. Opsonic activity of human ascitic fluid: a potentially important protective mechanism against spontaneous bacterial peritonitis. Hepatology 1985, 5:634-637.
20. Gomez F., Ruiz P., Schreiber A.D. Impaired function of macrophage Fc gamma receptors and bacterial infection in alcoholic cirrhosis. N Engl J Med 1994, 331:1122-1128.
21. Ferri C., Antonelli A., Mascia M.T., et al. HCV-related autoimmune and neoplastic disorders: the HCV syndrome. Dig Liver Dis 2007, 39(Suppl 1):S13-S21.
22. Romeo J., Warnberg J., Marcos A. Drinking pattern and socio-cultural aspects on immune response: an overview. Proc Nutr Soc 2010, 69:341-346.
23. Laso F.J., Lapeña P., Madruga J.I., et al. Alterations in tumor necrosis factor-alpha, interferon-gamma, and interleukin-6 production by natural killer cell-enriched peripheral blood mononuclear cells in chronic alcoholism: relationship with liver disease and ethanol intake. Alcohol Clin Exp Res 1997, 21:1226-1231.
24. Wiest R., Garcia-Tsao G. Bacterial translocation (BT) in cirrhosis. Hepatology 2005, 41:422-433.
25. Chang C.S., Chen G.H., Lien H.C., et al. Small intestine dysmotility and bacterial overgrowth in cirrhotic patients with spontaneous bacterial peritonitis. Hepatology 1998, 28:1187-1190.
26. Chesta J., Defilippi C., Defilippi C. Abnormalities in proximal small bowel motility in patients with cirrhosis. Hepatology 1993, 17:828-832.
27. Follo A., Llovet J.M., Navasa M., et al. Renal impairment after spontaneous bacterial peritonitis in cirrhosis: incidence, clinical course, predictive factors and prognosis. Hepatology 1994, 20:1495-1501.
28. Sort P., Navasa M., Arroyo V., et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 1999, 341:403-409.
29. Terra C., Guevara M., Torre A., et al. Renal failure in patients with cirrhosis and sepsis unrelated to spontaneous bacterial peritonitis: value of MELD score. Gastroenterology 2005, 129:1944-1953.
30. Fasolato S., Angeli P., Dallagnese L., et al. Renal failure and bacterial infections in patients with cirrhosis: epidemiology and clinical features. Hepatology 2007, 45:223-229.
31. Wong F., Bernardi M., Balk R., et al. Sepsis in cirrhosis: report on the 7th meeting of the International Ascites Club. Gut 2005, 54:718-725.
32. Gustot T., Durand F., Lebrec D., et al. Severe sepsis in cirrhosis. Hepatology 2009, 50:2022-2033.
33. Cazzaniga M., Dionigi E., Gobbo G., et al. The systemic inflammatory response syndrome in cirrhotic patients: relationship with their in-hospital outcome. J Hepatol 2009, 51:475-482.
34. Chan C.C., Hwang S.J., Lee F.Y., et al. Prognostic value of plasma endotoxin levels in patients with cirrhosis. Scand J Gastroenterol 1997, 32:942-946.
35. Byl B., Roucloux I., Crusiaux A., et al. Tumor necrosis factor alpha and interleukin 6 plasma levels in infected cirrhotic patients. Gastroenterology 1993, 104:1492-1497.
36. Wang S.S., Lee F.Y., Chan C.C., et al. Sequential changes in plasma cytokine and endotoxin levels in cirrhotic patients with bacterial infection. Clin Sci (Lond) 2000, 98:419-425.
37. Plessier A., Denninger M.H., Consigny Y., et al. Coagulation disorders in patients with cirrhosis and severe sepsis. Liver Int 2003, 23:440-448.
38. Lee K.C., Yang Y.Y., Wang Y.W., et al. Increased plasma malondialdehyde in patients with viral cirrhosis and its relationships to plasma nitric oxide, endotoxin, and portal pressure. Dig Dis Sci 2010, 55:2077-2085.
39. Guarner C., Soriano G., Tomas A., et al. Increased serum nitrite and nitrate levels in patients with cirrhosis: relationship to endotoxemia. Hepatology 1993, 18:1139-1143.
40. Tsai M.H., Peng Y.S., Chen Y.C., et al. Adrenal insufficiency in patients with cirrhosis, severe sepsis and septic shock. Hepatology 2006, 43:673-681.
41. Fernández J., Escorsell A., Zabalza M., et al. Adrenal insufficiency in patients with cirrhosis and septic shock: effect of treatment with hydrocortisone on survival. Hepatology 2006, 44:1288-1295.
42. Marik P.E., Gayowski T., Starzl T.E. The hepatoadrenal syndrome: a common yet unrecognized clinical condition. Crit Care Med 2005, 33:1254-1259.
43. Annane D., Sébille V., Charpentier C., et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 2002, 288:862-871.
44. Sprung C.L., Annane D., Keh D., et al. Hydrocortisone therapy for patients with septic shock. N Engl J Med 2008, 358:111-124.
45. Arabi Y.M., Aljumah A., Dabbagh O., et al. Low-dose hydrocortisone in patients with cirrhosis and septic shock: a randomized controlled trial. CMAJ 2010, 182:1971-1977.
46. Bernard B., Grangé J.D., Khac E.N., et al. Antibiotic prophylaxis for the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding: a meta-analysis. Hepatology 1999, 29:1655-1661.
47. Bernard B., Cadranel J.F., Valla D., et al. Prognostic significance of bacterial infection in bleeding cirrhotic patients: a prospective study. Gastroenterology 1995, 108:1828-1834.
48. Vivas S., Manuel R., Palacio A., et al. Presence of bacterial infection in bleeding cirrhotic patients is independently associated with early mortality and failure to control bleeding. Dig Dis Sci 2001, 46:2752-2757.
49. Goulis J., Patch D., Burroughs A.K. Bacterial infection in the pathogenesis of variceal bleeding. Lancet 1999, 353:139-142.
50. Caly W.R., Strauss E. A prospective study of bacterial infections in patients with cirrhosis. J Hepatol 1993, 18:353-358.
51. Fernández J., Ruiz del Arbol L., Gómez C., et al. Norfloxacin vs ceftriaxone in the prophylaxis of infections in patients with advanced cirrhosis and hemorrhage. Gastroenterology 2006, 131:1049-1056.
52. Jun C.H., Park C.H., Lee W.S., et al. Antibiotic prophylaxis using third generation cephalosporins can reduce the risk of early rebleeding in the first acute gastroesophageal variceal hemorrhage: a prospective randomized study. J Korean Med Sci 2006, 21:883-890.
53. Hou M.C., Lin H.C., Liu T.T., et al. Antibiotic prophylaxis after endoscopic therapy prevents rebleeding in acute variceal hemorrhage: a randomized trial. Hepatology 2004, 39:746-753.
54. Chavez-Tapia N.C., Barrientos-Gutierrez T., Tellez-Avila F.I., et al. Antibiotic prophylaxis for cirrhotic patients with upper gastrointestinal bleeding. Cochrane Database Syst Rev 2010, CD002907.
55. Senzolo M., Cholongitas E., Burra P., et al. Beta-Blockers protect against spontaneous bacterial peritonitis in cirrhotic patients: a meta-analysis. Liver Int 2009, 29:1189-1193.
56. Chelarescu O., Chelarescu D., Tircoveanu E., et al. Propranolol administration on post surgical infections in cirrhotic patients. Am J Gastroenterol 2003, 38:A173.
57. Sersté T., Melot C., Francoz C., et al. Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites. Hepatology 2010, 52:1017-1022.
58. Wong F., Salerno F. Beta-blockers in cirrhosis: friend and foe?. Hepatology 2010, 52:811-813.
59. Sandhu B.S., Gupta R., Sharma J., et al. Norfloxacin and cisapride combination decreases the incidence of spontaneous bacterial peritonitis in cirrhotic ascites. J Gastroenterol Hepatol 2005, 20:599-605.
60. Liu Q., Duan Z.P., Ha D.K., et al. Synbiotic modulation of gut flora: effect on minimal hepatic encephalopathy in patients with cirrhosis. Hepatology 2004, 39:1441-1449.
61. Tandon P., Moncrief K., Madsen K., et al. Effects of probiotic therapy on portal pressure in patients with cirrhosis: a pilot study. Liver Int 2009, 29:1110-1115.
62. Pereg D., Kotliroff A., Gadoth N., et al. Probiotics for patients with compensated liver cirrhosis: a double-blind placebo-controlled study. Nutrition 2011, 27:177-181.
63. Rimola A., García-Tsao G., Navasa M., et al. Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document. International Ascites Club. J Hepatol 2000, 32:142-153.
64. Thuluvath P.J., Morss S., Thompson R. Spontaneous bacterial peritonitis--in-hospital mortality, predictors of survival, and health care costs from 1988 to 1998. Am J Gastroenterol 2001, 96:1232-1236.
65. Navasa M., Follo A., Llovet J.M., et al. Randomized, comparative study of oral ofloxacin versus intravenous cefotaxime in spontaneous bacterial peritonitis. Gastroenterology 1996, 111:1011-1017.
66. Runyon B.A. Management of adult patients with ascites due to cirrhosis: an update. Hepatology 2009, 49:2087-2107. AASLD Practice Guidelines Committee.
67. Runyon B.A., Canawati H.N., Akriviadis E.A. Optimization of ascitic fluid culture technique. Gastroenterology 1988, 95:1351-1355.
68. Bobadilla M., Sifuentes J., Garcia-Tsao G. Improved method for bacteriological diagnosis of spontaneous bacterial peritonitis. J Clin Microbiol 1989, 27:2145-2147.
69. Nguyen-Khac E., Cadranel J.F., Thevenot T., et al. Review article: the utility of reagent strips in the diagnosis of infected ascites in cirrhotic patients. Aliment Pharmacol Ther 2008, 28:282-288.
70. Mendler M.H., Agarwal A., Trimzi M., et al. A new highly sensitive point of care screen for spontaneous bacterial peritonitis using the leukocyte esterase method. J Hepatol 2010, 53:477-483.
71. Rogers G.B., Russell L.E., Preston P.G., et al. Characterisation of bacteria in ascites-reporting the potential of culture-independent, molecular analysis. Eur J Clin Microbiol Infect Dis 2010, 29:533-541.
72. Bruns T., Sachse S., Straube E., et al. Identification of bacterial DNA in neutrocytic and non-neutrocytic cirrhotic ascites by means of a multiplex polymerase chain reaction. Liver Int 2009, 29:1206-1214.
73. Soriano G., Castellote J., Alvarez C., et al. Secondary bacterial peritonitis in cirrhosis: a retrospective study of clinical and analytical characteristics, diagnosis and management. J Hepatol 2010, 52:39-44.
74. Wu S.S., Lin O.S., Chen Y.Y., et al. Ascitic fluid carcinoembryonic antigen and alkaline phosphatase levels for the differentiation of primary from secondary bacterial peritonitis with intestinal perforation. J Hepatol 2001, 34:215-221.
75. Mazuski J.E., Sawyer R.G., Nathens A.B., et al. The Surgical Infection Society guidelines on antimicrobial therapy for intra-abdominal infections: an executive summary. Surg Infect (Larchmt) 2002, 3:161-173.
76. Runyon B.A., Hoefs J.C. Culture-negative neutrocytic ascites: a variant of spontaneous bacterial peritonitis. Hepatology 1984, 4:1209-1211.
77. Runyon B.A., Hoefs J.C., Canawati H.N. Polymicrobial bacterascites. A unique entity in the spectrum of infected ascitic fluid. Arch Intern Med 1986, 146:2173-2175.
78. Runyon B.A. Monomicrobial nonneutrocytic bacterascites: a variant of spontaneous bacterial peritonitis. Hepatology 1990, 12:710-715.
79. Akriviadis E.A., Runyon B.A. Utility of an algorithm in differentiating spontaneous from secondary bacterial peritonitis. Gastroenterology 1990, 98:127-133.
80. Rimola A., Salmerón J.M., Clemente G., et al. Two different dosages of cefotaxime in the treatment of spontaneous bacterial peritonitis in cirrhosis: results of a prospective, randomized, multicenter study. Hepatology 1995, 21:674-679.
81. Simmons B.P., Gelfand M.S., Grogan J., et al. Cefotaxime twice daily versus ceftriaxone once daily. A randomized controlled study in patients with serious infections. Diagn Microbiol Infect Dis 1995, 22:155-157.
82. Yakar T., Güçlü M., Serin E., et al. A recent evaluation of empirical cephalosporin treatment and antibiotic resistance of changing bacterial profiles in spontaneous bacterial peritonitis. Dig Dis Sci 2010, 55:1149-1154.
83. Angeli P., Guarda S., Fasolato S., et al. Switch therapy with ciprofloxacin vs. intravenous ceftazidime in the treatment of spontaneous bacterial peritonitis in patients with cirrhosis: similar efficacy at lower cost. Aliment Pharmacol Ther 2006, 23:75-84.
84. Chen T.A., Tsao Y.C., Chen A., et al. Effect of intravenous albumin on endotoxin removal, cytokines, and nitric oxide production in patients with cirrhosis and spontaneous bacterial peritonitis. Scand J Gastroenterol 2009, 44:619-625.
85. Fernández J., Navasa M., Garcia-Pagan J.C., et al. Effect of intravenous albumin on systemic and hepatic hemodynamics and vasoactive neurohormonal systems in patients with cirrhosis and spontaneous bacterial peritonitis. J Hepatol 2004, 41:384-390.
86. Jalan R., Schnurr K., Mookerjee R.P., et al. Alterations in the functional capacity of albumin in patients with decompensated cirrhosis is associated with increased mortality. Hepatology 2009, 50:555-564.
87. Terg R., Gadano A., Cartier M., et al. Serum creatinine and bilirubin predict renal failure and mortality in patients with spontaneous bacterial peritonitis: a retrospective study. Liver Int 2009, 29:415-419.
88. Cartier M., Terg R., Lucero R., et al. Pilot study: Gelafundin (polygeline) 4% plus antibiotics in the treatment of high-risk cirrhotic patients with spontaneous bacterial peritonitis. Aliment Pharmacol Ther 2009, 32:43-48.
89. Toledo C., Salmerón J.M., Rimola A., et al. Spontaneous bacterial peritonitis in cirrhosis: predictive factors of infection resolution and survival in patients treated with cefotaxime. Hepatology 1993, 17:251-257.
90. França A.V., De Souza J.B., Silva C.M., et al. Long-term prognosis of cirrhosis after spontaneous bacterial peritonitis treated with ceftriaxone. J Clin Gastroenterol 2001, 33:295-298.
91. Titó L., Rimola A., Ginès P., et al. Recurrence of spontaneous bacterial peritonitis in cirrhosis: frequency and predictive factors. Hepatology 1988, 8:27-31.
92. Ginés P., Rimola A., Planas R., et al. Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: results of a double-blind, placebo-controlled trial. Hepatology 1990, 12:716-724.
93. Rolachon A., Cordier L., Bacq Y., et al. Ciprofloxacin and long-term prevention of spontaneous bacterial peritonitis: results of a prospective controlled trial. Hepatology 1995, 22:1171-1174.
94. Terg R., Llano K., Cobas S.M., et al. Effects of oral ciprofloxacin on aerobic gram-negative fecal flora in patients with cirrhosis: results of short- and long-term administration, with daily and weekly dosages. J Hepatol 1998, 29:437-442.
95. Singh N., Gayowski T., Yu V.L., et al. Trimethoprim-sulfamethoxazole for the prevention of spontaneous bacterial peritonitis in cirrhosis: a randomized trial. Ann Intern Med 1995, 122:595-598.
96. Guarner C., Runyon B.A., Heck M., et al. Effect of long-term trimethoprim-sulfamethoxazole prophylaxis on ascites formation, bacterial translocation, spontaneous bacterial peritonitis, and survival in cirrhotic rats. Dig Dis Sci 1999, 44:1957-1962.
97. Loomba R., Wesley R., Bain A., et al. Role of fluoroquinolones in the primary prophylaxis of spontaneous bacterial peritonitis: meta-analysis. Clin Gastroenterol Hepatol 2009, 7:487-493.
98. Fernández J., Navasa M., Planas R., et al. Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis. Gastroenterology 2007, 133:818-824.
99. Cadranel J.F., Denis J., Pauwels A., et al. Prevalence and risk factors of bacteriuria in cirrhotic patients: a prospective case-control multicenter study in 244 patients. J Hepatol 1999, 31:464-468.
100. Rabinovitz M., Prieto M., Gavaler J.S., et al. Bacteriuria in patients with cirrhosis. J Hepatol 1992, 16:73-76.
101. Amato A., Precone D., Carannante N., et al. Prevalence and risk factors for bacteriuria in patients with cirrhosis. Infez Med 2005, 2:103-108.
102. Bercoff E., Dechelotte P., Weber J., et al. Urinary tract infection in cirrhotic patients, an urodynamic explanation. Lancet 1985, 325:987.
103. Mellencamp M.A., Preheim L.C. Pneumococcal pneumonia in a rat model of cirrhosis: effects of cirrhosis on pulmonary defense mechanisms against Streptococcus pneumoniae. J Infect Dis 1991, 163:102-108.
104. Niederman M.S., Mandell L.A., Anzueto A., et al. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001, 163:1730-1754.
105. Falguera M., Trujillano J., Caro S., et al. A prediction rule for estimating the risk of bacteremia in patients with community-acquired pneumonia. Clin Infect Dis 2009, 49:409-416.
106. Yang Y.Y., Lin H.C. Bacterial Infections in Patients with Cirrhosis. J Chin Med Assoc 2005, 68:447-451.
107. Mehta G., Rothstein K.D. Health maintenance issues in cirrhosis. Med Clin North Am 2009, 93:901-915. viii-ix.
108. Liu B.M., Chung K.J., Chen C.H., et al. Risk factors for the outcome of cirrhotic patients with soft tissue infections. J Clin Gastroenterol 2008, 42:312-316.
109. Rongey C., Lim N.H., Runyon B.A. Cellulitis in patients with cirrhosis and edema: an under-recognized complication currently more common than spontaneous bacterial peritonitis. The Open Gastroenterol Journal 2008, 2:24-27.
110. Lee C.C., Chi C.H., Lee N.Y., et al. Necrotizing fasciitis in patients with liver cirrhosis: predominance of monomicrobial Gram-negative bacillary infections. Diagn Microbiol Infect Dis 2008, 62:219-225.
111. Cheng N.C., Tai H.C., Tang Y.B., et al. Necrotising fasciitis: clinical features in patients with liver cirrhosis. Br J Plast Surg 2005, 58:702-707.
112. Fernández Guerrero M.L., González López J., Górgolas M. Infectious endocarditis in patients with cirrhosis of the liver: a model of infection in the frail patient. Eur J Clin Microbiol Infect Dis 2010, 29:1271-1275.
113. Fernández-Guerrero M.L., Herrero L., Bellver M., et al. Nosocomial enterococcal endocarditis: a serious hazard for hospitalized patients with enterococcal bacteraemia. J Intern Med 2002, 252:510-515.
114. Baddour L.M., Wilson W.R., Bayer A.S., et al. Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America. Circulation 2005, 111:e394-e434.
115. An Y., Xiao Y.B., Zhong Q.J. Open-heart surgery in patients with liver cirrhosis: indications, risk factors, and clinical outcomes. Eur Surg Res 2007, 39:67-74.
116. Thulstrup A.M., Mølle I., Svendsen N., et al. Incidence and prognosis of tuberculosis in patients with cirrhosis of the liver. A Danish nationwide population based study. Epidemiol Infect 2000, 124:221-225.
117. Cho Y.J., Lee S.M., Yoo C.G., et al. Clinical characteristics of tuberculosis in patients with liver cirrhosis. Respirology 2007, 12:401-405.
118. Kim N.J., Choo E.J., Kwak Y.G., et al. Tuberculous peritonitis in cirrhotic patients: comparison of spontaneous bacterial peritonitis caused by Escherichia coli with tuberculous peritonitis. Scand J Infect Dis 2009, 41:852-856.
119. Hillebrand D.J., Runyon B.A., Yasmineh W.G., et al. Ascitic fluid adenosine deaminase insensitivity in detecting tuberculous peritonitis in the United States. Hepatology 1996, 24:1408-1412.
120. Reddy K.R., DiPrima R.E., Raskin J.B., et al. Tuberculous peritonitis: laparoscopic diagnosis of an uncommon disease in the United States. Gastrointest Endosc 1988, 34:422-426.
121. Bajaj J.S., Ananthakrishnan A.N., Hafeezullah M., et al. Clostridium difficile is associated with poor outcomes in patients with cirrhosis: a national and tertiary center perspective. Am J Gastroenterol 2010, 105:106-113.
122. Garcia-Tsao G., Surawicz C.M. Editorial: Clostridium difficile infection: yet another predictor of poor outcome in cirrhosis. Am J Gastroenterol 2010, 105:114-116.
123. Cheong H.S., Kang C.I., Lee J.A., et al. Clinical significance and outcome of nosocomial acquisition of spontaneous bacterial peritonitis in patients with liver cirrhosis. Clin Infect Dis 2009, 48:1230-1236.
124. Merli M., Lucidi C., Giannelli V., et al. Cirrhotic patients are at risk for health care-associated bacterial infections. Clin Gastroenterol Hepatol 2010, 8:979-985.
125. Campillo B., Richardet J.P., Kheo T., et al. Nosocomial spontaneous bacterial peritonitis and bacteremia in cirrhotic patients: impact of isolate type on prognosis and characteristics of infection. Clin Infect Dis 2002, 35:1-10.
126. McBride S.J., Upton A., Roberts S.A. Clinical characteristics and outcomes of patients with vancomycin-susceptible Enterococcus faecalis and Enterococcus faecium bacteraemia-a five-year retrospective review. Eur J Clin Microbiol Infect Dis 2010, 29:107-114.
127. Bhavnani S.M., Drake J.A., Forrest A., et al. A nationwide, multicenter, case-control study comparing risk factors, treatment, and outcome for vancomycin-resistant and -susceptible enterococcal bacteremia. Diagn Microbiol Infect Dis 2000, 36:145-158.
128. Park M.K., Lee J.H., Byun Y.H., et al. Changes in the profiles of causative agents and antibiotic resistance rate for spontaneous bacterial peritonitis: an analysis of cultured microorganisms in recent 12 years [in Korean]. Korean J Hepatol 2007, 13:370-377.
129. Albert-Braun S., Venema F., Bausch J., et al. Cryptococcus neoformans peritonitis in a patient with alcoholic cirrhosis: case report and review of the literature. Infection 2005, 33:282-288.
130. Mabee C.L., Mabee S.W., Kirkpatrick R.B., et al. A risk factor for cryptococcal peritonitis. Am J Gastroenterol 1995, 90:2042-2045.
131. Jean S.S., Fang C.T., Shau W.Y., et al. Cryptococcaemia: clinical features and prognostic factors. QJM 2002, 95:511-518.
132. Park W.B., Choe Y.J., Lee K.D., et al. Spontaneous cryptococcal peritonitis in patients with liver cirrhosis. Am J Med 2006, 119:169-171.
133. Saif M.W., Raj M. Cryptococcal peritonitis complicating hepatic failure: case report and review of the literature. J Appl Res 2006, 6:43-50.
134. Lenz P., Conrad B., Kucharzik T., et al. Prevalence, associations, and trends of biliary-tract candidiasis: a prospective observational study. Gastrointest Endosc 2009, 70:480-487.
135. Kulaksiz H., Rudolph G., Kloeters-Plachky P., et al. Biliary Candida infections in primary sclerosing cholangitis. J Hepatol 2006, 45:711-716.
136. Khan F.A., Fisher M.A., Khakoo R.A. Association of hemochromatosis with infectious diseases: expanding spectrum. Int J Infect Dis 2007, 11:482-487.
137. Ashrafian H. Hepcidin: the missing link between hemochromatosis and infections. Infect Immun 2003, 71:6693-6700.
138. Kizer K.W. Vibrio vulnificus hazard in patients with liver disease. West J Med 1994, 161:64-65.
139. Brann O.S. Infectious complications of cirrhosis. Curr Gastroenterol Rep 2001, 3:285-292.
140. Vadillo M., Corbella X., Pac V., et al. Multiple liver abscesses due to Yersinia enterocolitica discloses primary hemochromatosis: three cases reports and review. Clin Infect Dis 1994, 18:938-941.
141. Olesen L.L., Ejlertsen T., Paulsen S.M., et al. Liver abscesses due to Yersinia enterocolitica in patients with haemochromatosis. J Intern Med 1989, 225:351-354.
142. Mennecier D., Lapprand M., Hernandez E., et al. Liver abscesses due to Yersinia pseudotuberculosis discloses a genetic hemochromatosis [in French]. Gastroenterol Clin Biol 2001, 25:1113-1115.
143. Melzer M., Toner R., Lacey S., et al. Biliary tract infection and bacteraemia: presentation, structural abnormalities, causative organisms and clinical outcomes. Postgrad Med J 2007, 83:773-776.
144. Subhani J.M., Kibbler C., Dooley J.S. Review article: antibiotic prophylaxis for endoscopic retrograde cholangiopancreatography (ERCP). Aliment Pharmacol Ther 1999, 13:103-116.
145. Olsson R., Björnsson E., Bäckman L., et al. Bile duct bacterial isolates in primary sclerosing cholangitis: a study of explanted livers. J Hepatol 1998, 28:426-432.
146. Pohl J., Ring A., Stremmel W., et al. The role of dominant stenoses in bacterial infections of bile ducts in primary sclerosing cholangitis. Eur J Gastroenterol Hepatol 2006, 18:69-74.